Core Viewpoint - Nanyang Biologics, a Singapore-based AI drug discovery start-up, plans to go public on Nasdaq in Q1 2026 through a merger with a SPAC, amid US tariffs on pharmaceutical imports [1][4]. Company Initiatives - The company aims to license its early-stage drug assets to US manufacturers, aligning with the Trump administration's goals, while minimizing the impact of US tariff issues on its operations [2]. - Nanyang Biologics has five drug candidates targeting cancer and cardiovascular diseases and plans to expand research into stress-related disorders and dementia [3]. Financial Aspects - Proceeds from the Nasdaq listing will be used to enhance the company's technology platform and develop its therapeutic pipeline [4]. - The merger with RF Acquisition Corp II values Nanyang Biologics at US$1.5 billion, with plans to list under the ticker symbol NYB post-merger [6]. Market Context - The Trump administration announced a 100% tariff on brand-name or patented pharmaceutical products effective October 1, unless manufacturers establish production facilities in the US [4]. - Trump has indicated a potential delay of one to one and a half years for the tariffs, allowing companies time to adjust their manufacturing strategies [5]. Partnership Developments - Nanyang Biologics is in discussions with two potential global partners for licensing its early-stage drug assets, although details on the size or timeline of these deals remain undisclosed [5].